STOCK TITAN

UNITED THERAPEUTICS (UTHR) CFO exercises options and sells 10,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 10,000 shares of Common Stock at an exercise price of $117.76 per share and, on the same date, sold 10,000 shares of Common Stock in a series of open-market trades at weighted average prices generally around the mid‑$540s to mid‑$550s per share. The filing states that this option exercise and subsequent share sales were carried out under a pre-arranged Rule 10b5‑1 trading plan. Following these transactions, Edgemond directly owns 18,876 shares of UNITED THERAPEUTICS Common Stock.

Positive

  • None.

Negative

  • None.
Insider EDGEMOND JAMES
Role CFO AND TREASURER
Sold 10,000 shs ($5.48M)
Type Security Shares Price Value
Exercise Stock Option 10,000 $0.00 --
Exercise Common Stock 10,000 $117.76 $1.18M
Sale Common Stock 1,440 $544.9599 $785K
Sale Common Stock 2,520 $546.2253 $1.38M
Sale Common Stock 1,354 $547.1116 $741K
Sale Common Stock 1,606 $548.2639 $881K
Sale Common Stock 1,185 $549.2972 $651K
Sale Common Stock 1,015 $550.1955 $558K
Sale Common Stock 200 $550.81 $110K
Sale Common Stock 280 $552.9157 $155K
Sale Common Stock 400 $554.471 $222K
Holdings After Transaction: Stock Option — 40,000 shares (Direct, null); Common Stock — 28,876 shares (Direct, null)
Footnotes (1)
  1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $544.67 to $545.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $545.75 to $546.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $546.75 to $547.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $547.76 to $548.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $548.78 to $549.775. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $549.78 to $550.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $552.76 to $553.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $553.97 to $554.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 10,000 shares Common Stock sold in open-market trades on 2026-06-01
Shares acquired via option exercise 10,000 shares Common Stock acquired through option exercise on 2026-06-01
Option exercise price $117.76 per share Exercise price for 10,000-share stock option
Post-transaction holdings 18,876 shares Common Stock directly owned after transactions
Option expiration date 2027-03-15 Expiration date of exercised stock option
Net share change from trades -10,000 shares Net of 10,000 shares sold and 10,000 shares exercised
Rule 10b5-1 trading plan regulatory
"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Common Stock financial
"security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EDGEMOND JAMES

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO AND TREASURER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026M(1)10,000A$117.7628,876D
Common Stock06/01/2026S(1)1,440D$544.9599(2)27,436D
Common Stock06/01/2026S(1)2,520D$546.2253(3)24,916D
Common Stock06/01/2026S(1)1,354D$547.1116(4)23,562D
Common Stock06/01/2026S(1)1,606D$548.2639(5)21,956D
Common Stock06/01/2026S(1)1,185D$549.2972(6)20,771D
Common Stock06/01/2026S(1)1,015D$550.1955(7)19,756D
Common Stock06/01/2026S(1)200D$550.8119,556D
Common Stock06/01/2026S(1)280D$552.9157(8)19,276D
Common Stock06/01/2026S(1)400D$554.471(9)18,876D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$117.7606/01/2026M(1)10,00003/15/202303/15/2027Common Stock10,000$0.0040,000D
Explanation of Responses:
1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
2. This transaction was executed in multiple trades at prices ranging from $544.67 to $545.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $545.75 to $546.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $546.75 to $547.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $547.76 to $548.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $548.78 to $549.775. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $549.78 to $550.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $552.76 to $553.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $553.97 to $554.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney06/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did UNITED THERAPEUTICS (UTHR) report for CFO James Edgemond?

CFO James Edgemond exercised options and sold shares of UNITED THERAPEUTICS Common Stock. He acquired 10,000 shares through an option exercise and sold 10,000 shares in multiple open-market trades on the same date.

How many UNITED THERAPEUTICS (UTHR) shares did the CFO sell and at what prices?

The CFO sold 10,000 shares of UNITED THERAPEUTICS Common Stock. The sales occurred in multiple trades with weighted average prices generally between about $544 and $555 per share, as detailed in the individual transaction price disclosures.

At what price did the UNITED THERAPEUTICS (UTHR) CFO exercise stock options?

He exercised stock options covering 10,000 shares of UNITED THERAPEUTICS Common Stock at an exercise price of $117.76 per share. These options related to a stock option award with an indicated expiration date in March 2027.

Were the UNITED THERAPEUTICS (UTHR) CFO’s trades under a Rule 10b5-1 plan?

Yes. The filing specifies that the option exercise and subsequent sale of shares by the UNITED THERAPEUTICS CFO were executed pursuant to a Rule 10b5-1 trading plan entered into on October 31, 2025, indicating the transactions were pre-scheduled.

How many UNITED THERAPEUTICS (UTHR) shares does the CFO hold after these transactions?

After completing the option exercise and related sales, the UNITED THERAPEUTICS CFO directly owns 18,876 shares of Common Stock. This post-transaction holding amount is reported in the Form 4 as the total shares following the final transaction.